Careplus Group Bhd

Careplus Group Bhd exhibits a weak capital structure and liquidity position, with a negative operating cash flow of MYR -7,269,030 and a free cash flow of MYR -85,702,260. The company's debt-to-equity ratio is 0.15, indicating a relatively low level of leverage, but its current ratio of 1.58 suggests moderate short-term liquidity. The negative net cash position after subtracting total debt raises concerns about its ability to meet short-term obligations without external financing. Profitability metrics are severely negative, with a return on equity of -37.75% and a return on assets of -28.48%. These figures are well below the typical performance of companies in the Medical Equipment, Supplies & Distribution industry, which usually exhibit positive returns. The company reported a net loss of MYR 81,628,350, with operating income also in negative territory at MYR -76,166,720, indicating significant operational challenges. The company's revenue is concentrated in the manufacturing and sale of medical gloves, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The company's primary subsidiaries are focused on glove manufacturing and distribution, with no significant revenue streams from other business lines. Growth trajectory appears negative, with the company reporting a revenue of MYR 98,929,320 in the latest period. Analyst estimates suggest a previous actual revenue of MYR 322,574,500, indicating a significant decline. The company's capital expenditure of MYR -18,142,330 suggests a reduction in investment, which may further hinder future growth. Risk factors include a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag. The ESG controversies score of 100.0 indicates significant environmental, social, and governance issues, which could impact its reputation and regulatory compliance. Recent events include a notable decline in revenue and profitability, as well as a high ESG controversies score. The company has not disclosed any recent filings or transcripts that provide additional context on its financial performance or strategic direction.